Autosomal dominant polycystic kidney disease (ADPKD) is an inherited systemic disorder mainly associated with mutations in the PKD1 gene and characterized by the development of multiple cysts in the kidneys and other organs. There is still a high unmet need for treatment options for patients with ADPKD because Tolvaptan, the only approved treatment, has limited efficacy and non-negligible side effects. To mimic naturally occurring human PKD1 mutations, a PKD1 inducible knockout mice strain was established at Novalix to study disease progression and evaluate therapeutic approaches.
Why Visiopharm’s Discovery software helps
The software enabled comprehensive histological and imaging analyses, providing actionable insights into the disease mechanisms and progression.
